Adam Klipfel, MD
Colon & Rectal Surgery · Providence, RINPI 1114988243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,958 of the $2,890 with a category attached, or 67.7%. Davol Inc. accounts for 67.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $2,358 and has fallen 97.6% since, to $57 in 2025.
Across 14 payments — averaging $206.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- Medtronic$609
- Intuitive Surgical$193
- Merck$101
- Vertex$30
Across 66 payments — averaging $5642.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$314K
- Reddress LTD$58K
What the payments were for
- Speaking & faculty fees$1,95868%
- Travel & lodging$321%
- Food & beverage$90031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $1,958 |
| Medtronic | 9 | $609 |
| Intuitive Surgical | 2 | $193 |
| Merck | 1 | $101 |
| Vertex | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$180
- GI Genius$135
- INTERSTIM$117
- Sonicision$114
- BRIDION$101
How this compares
Too few colon & rectal surgery providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 61 | $383 |
| Hydrocortisone | 19 | $303 |
| Metronidazole | 64 | $109 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $104 |
| Ondansetron Hcl | 57 | $42 |
| Gabapentin | 42 | $24 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Providence
- Steven SchechterProvidence$45K
- Matthew VreesProvidence$8K
- Leslie RothProvidence$7K
- Rebecca GologorskyProvidence$1K
- Thomas CataldoProvidence$533
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.